学会発表
Clinical efficacy of eribulin as a first- or second-line treatment for patients with recurrent HER2-negative breast cancer : a phase II randomized study (JBCRG-19)
Kenichi Watanabe, Kenjiro Aogi, Masahiro Kitada, Takafumi Sangai, Shoichiro Ohtani, Tomoyuki Aruga, Hidetoshi Kawaguchi, Tomomi Fujisawa, Shigeto Maeda, Takashi Morimoto, Satoshi Morita, Norikazu Masuda, Masakazu Toi, Shinji Ohno
2018.10 ESMO Poster Munich, Germany
Evaluation of the safety of neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with docetaxel and cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-11TC)
Koji Kaneko, Nobuaki Sato, Hiroyuki Yasojima, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
第56回日本癌治療学会学術集会 Yokohama, JAPAN 2018年10月
閉経後ER陽性進行・再発乳癌におけるフルベストラントの至適投与方法の検討（JBCRG-C06: Safari）
川口英俊、増田慎三、中山貴寛、青儀健二郎、阿南敬生、伊藤良則、大谷彰一郎、佐藤信昭、佐治重衡、徳永えり子、中村清吾、長谷川善枝、藤澤知巳、山口美樹、山下年成、山本豊、森田智視、大野真司、戸井雅和
第26回日本乳癌学会学術集会 Kyoto, JAPAN 2018年5月
TrastuzumabとPertuzumabの同時混合点滴の安全性に関する検討 (JBCRG-20 sub-study)
坂東裕子、増田慎三、伊藤良則、石田和茂、井口研子、水谷麻紀子、小林 心、柏葉匡寛、八十島宏行、笠井宏委、高須賀剛、森田智視、大野真司、戸井雅和
第26回日本乳癌学会学術集会 Kyoto, JAPAN 2018年5月
Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)
Masahiro Kashiwaba, Yutaka Yamamoto, Hidetoshi Yamashiro, Naoto Kondo, Rikiya Nakamura, Masato Takahashi, Uhi Toh, Koichiro Tsugawa, Kazutaka Narui, Kentaro Tamaki, Tetsuhiro Yoshinami, Shoichiro Ohtani, Yuichiro Kai, Toshimi Takano, Yasuhiro Yanagita, Satoshi Morita, Masakazu Toi, Shinji Ohno
2018.3 EBCC Poster Barcelona, Spain
Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer
Norikazu Masuda, Nobuaki Sato, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
2017.12 SABCS poster San Antonio, USA
閉経後HR乳癌患者に対するレスポンスガイド下術前内分泌療法 (JBCRG-11CPA)
森本卓，佐藤信昭，増田慎三，上野貴之，神林智寿子、金子耕司、八十島宏行、佐藤友威、新宮聖士、田邊匡、尾崎慎治、笹野公伸、森田智視、大野真司，戸井雅和
第55回日本癌治療学会学術集会, 2017 Oct, Yokohama Japan (ワークショップ)
Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer: A subgroup analysis of the JBCRG-C06 Safari study
Kenjiro Aogi, Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano Eriko Tokunaga, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi and Shinji Ohno
2017.9 ESMO Poster Madrid
Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20)
Norikazu Masuda, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Eiji Suzuki, Rikiya Nakamura, Hiroko Bando, Yoshinori Ito, Kazushige Ishida, Takashi Yamanaka, Katsumasa Kuroi, Hiroyuki Yasojima, Hiroi Kasai, Tsuyoshi Takasuka, Takaki Sakurai, Tatsuki R. Kataoka, Satoshi Morita, Shinji Ohno, Masakazu Toi
2017.9 ESMO Poster Madrid
Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03)
Kazutaka Narui, Toshinari Yamashita, Masahiro Kitada, Hidetoshi Kawaguchi, Masaya Hattori, Tetsuhiro Yoshinami, Nobuki Matsunami, Kazuhiro Yanagihara, Teru Kawasoe, Takeshi Nagashima, Hiroko Bando, Hiroshi Yano, Yoshie Hasegawa, Rikiya Nakamura, Masahiro Kashiwaba, Norikazu Masuda, Satoshi Morita, Shinji Ohno, Masakazu Toi
2017年6月 ASCO Poster Chicago